Therefore, if targeted HER-2/neu therapy using agents such as trastuzamab is to be employed in pancreatic cancer, and the mechanism of this therapy is mediated by AKT, then it would be anticipated that only tumours demonstrating significant AKT activation would respond. Here, AKT1 is linked to familial pancreatic carcinoma.